Vitrafy Life Sciences (ASX:VFY) has entered a 12-month exclusive collaboration and development agreement with global animal reproduction leader IMV Technologies, SA, a French multinational responsible for over 500 million animal inseminations annually.
The partnership will integrate Vitrafy’s next-generation nitrogen-free cryopreservation technology with IMV’s established reproductive solutions, aiming to jointly commercialise a global offering for farm animals and aquaculture.
Under the agreement, Vitrafy will receive up to $480,000 per month, with potential milestone payments of $450,000, while providing key hardware, software, and service support for pre-commercialisation activities.
Both companies will contribute resources to validate and deploy the technology, with the goal of establishing a long-term commercial agreement following the successful 12-month program.
Vitrafy CEO Brent Owens said the collaboration accelerates the adoption of its cryopreservation technology at scale while maintaining focus on human health expansion in North America.
IMV Technologies CEO Oliver Kohlhaas added that Vitrafy’s unique technology promises improved post-thaw cell viability, enhancing reproductive outcomes for their global customer base.